Janssen Pharmaceutical Inc.

NEWS

Drug Development

Biopharma Update on the Novel Coronavirus: September 4

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.

September 3, 2020

3 min read

BioSpace Editorial Staff

Pharm Country

J&J Abandons Influenza A Treatment Program After Interim Analysis

Janssen Pharmaceutical of Johnson & Johnson made a strategic call to halt development of pimodivir, an antiviral treatment for influenza A.

September 2, 2020

3 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: August 12

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.

August 11, 2020

5 min read

BioSpace Editorial Staff

Policy

Biopharma Update on the Novel Coronavirus: August 5

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.

August 4, 2020

5 min read

BioSpace Editorial Staff

Drug Development

Clinical Catch-Up: July 13-17

It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.

July 17, 2020

8 min read

Mark Terry

FDA

Janssen’s Tremfya Snags Approval as First IL-23 Treatment for Active Psoriatic Arthritis

In announcing the approval this morning, Janssen said IL-23 is a naturally occurring cytokine involved in normal inflammatory and immune responses associated with symptoms of psoriatic arthritis.

July 14, 2020

2 min read

Alex Keown

Policy

Biopharma Update on the Novel Coronavirus: July 6

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.

July 6, 2020

2 min read

BioSpace Editorial Staff

Business

Emergent and J&J Ink 5-Year COVID-19 Vaccine Manufacturing Deal

Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.

July 6, 2020

3 min read

Mark Terry

BioForest

Clinical Catch-Up: May 31-June 5

As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.

June 5, 2020

10 min read

Mark Terry

AWARDS

JOBS

IN THE PRESS

Pharm Country

IMBRUVICA® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control

May 19, 2021

17 min read

Pharm Country

Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization

May 16, 2021

16 min read

Drug Development

New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO)

April 23, 2021

21 min read

Business

PhysIQ Announces Strategic Collaboration to Scale Digital Medicine

April 20, 2021

3 min read

Biotech Bay

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

April 6, 2021

12 min read

Business

Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza

April 5, 2021

6 min read

Drug Development

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years

March 16, 2021

22 min read

Policy

Health Canada authorizes Janssen COVID-19 vaccine

March 5, 2021

1 min read

Lone Star Bio

Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101

March 2, 2021

4 min read

Lone Star Bio

McKesson Begins Distributing the Johnson & Johnson COVID-19 Vaccine

March 1, 2021

4 min read